三葉草生物-B(02197.HK)：《柳葉刀》刊發研究顯示SCB-2019(CpG 1018加鋁佐劑)在2/3期臨試證實其預防所有嚴重程度COVID-19的保護效力
格隆匯1月21日丨三葉草生物-B(02197.HK)發佈公吿，2022年1月21日，《柳葉刀》(同行評議的綜合醫學週刊)刊發了公司評估三葉草生物聯合佐劑使用的三聚體重組蛋白COVID-19候選疫苗的保護效力及安全性研究(“SPECTRA”)的最終保護效力數據，此為一項針對SCB-2019(CpG 1018加鋁佐劑)的全球關鍵性2/3期臨牀試驗。該研究顯示，接種兩劑公司的SCB-2019(CpG 1018加鋁佐劑)，可對當時正在傳播的SAR-CoV-2變異株造成的任何嚴重程度的COVID-19提供顯著保護效力。
公司正在向歐洲藥品管理局、中國國家藥品監督管理局及世界衞生組織提交附條件監管批准申請，並計劃在獲得附條件批准後開始上市其新冠疫苗產品。
目前正進行將SCB-2019(CpG 1018加鋁佐劑)作為COVID-19通用疫苗加強劑進行評估的試驗。SPECTRA試驗於2022年1月修訂，並開始將SCB-2019(CpG 1018加鋁佐劑)做為同源加強劑於約4000名成人受試者中進行評估。2021年11月，研究人員主導的II期臨牀試驗於巴西開始，將SCB-2019(CpG 1018加鋁佐劑)作為先前接種CoronaVac疫苗或重組Covid-19疫苗(阿斯利康╱Fiocruz)人士的加強劑進行評估。此等試驗的初步結果(包括針對奧密克戎變種的免疫原性數據)預計於2022年上半年發佈。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app！
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of this article is for reference only. It does not constitute an offer, solicitation, recommendation, opinion or guarantee of any securities, financial products or instruments.The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance.
